Estradiol hemihydrate (CAS No.: 50-28-2, hemihydrate form) is the pharmaceutically stabilized hemihydrate salt of 17β-estradiol—the primary and most biologically active endogenous estrogen in humans and mammals. As the gold standard of estrogen replacement therapy (ERT), it has identical physiological and pharmacological activity to natural 17β-estradiol but features improved physical and chemical stability, better solubility and more consistent bioavailability in pharmaceutical formulations (oral, transdermal, vaginal). Its core mechanism of action is binding selectively to nuclear estrogen receptors (ERα and ERβ) distributed in the reproductive system, bones, cardiovascular system, central nervous system (CNS) and skin; the estrogen-receptor complex translocates to the nucleus to regulate the transcription of target genes, thereby exerting a wide range of physiological and therapeutic effects on multiple organ systems. Estradiol hemihydrate is the first-line estrogen agent for clinical use, with its applications centered on hormone replacement therapy (HRT) for estrogen deficiency and the treatment of estrogen-dependent disorders in gynecology, reproductive medicine and endocrinology. It is also used in small animal veterinary medicine for estrogen deficiency-related conditions in female companion animals (dogs/cats).
Below is a systematic elaboration of its detailed clinical uses in human medicine (the primary application), auxiliary veterinary uses, formulation-specific application characteristics and key clinical notes, in line with the latest clinical guidelines of the International Menopause Society (IMS) and the American College of Obstetricians and Gynecologists (ACOG).
Core Clinical Uses: Human Medicine (Primary Indications)
Estradiol hemihydrate is the most widely used estrogen preparation in clinical practice, indicated for the prevention and treatment of all conditions caused by absolute or relative endogenous estrogen deficiency in women of different age groups (adolescents, premenopausal, menopausal and postmenopausal women). Its clinical applications are highly targeted, with dosage and administration route individualized according to the patient’s age, etiology of estrogen deficiency and clinical symptoms.
1. First-Line Indication: Menopausal Hormone Replacement Therapy (MHT/HRT)
This is the most common and core clinical use of estradiol hemihydrate, recommended as the first-line treatment for menopausal and postmenopausal women with moderate to severe estrogen deficiency symptoms by global medical guidelines. It is used for both peri-menopausal transition (40–55 years old) and post-menopause (>12 months after last menstrual period) women, effectively alleviating menopausal symptoms, preventing long-term estrogen deficiency-related complications and improving quality of life.
Relief of vasomotor symptoms (the most immediate therapeutic effect): It rapidly alleviates the classic menopausal vasomotor symptoms caused by fluctuating/declining estrogen levels, including hot flashes, night sweats, flushing and palpitations—the main reason women seek MHT. The therapeutic response rate is over 90% for moderate to severe symptoms, with symptom improvement observed within 1–2 weeks of administration.
Treatment of urogenital atrophy (genitourinary syndrome of menopause, GSM): Estrogen deficiency causes atrophy of the vaginal and urethral mucosa, leading to vaginal dryness, dyspareunia (painful intercourse), vaginal itching, recurrent vaginitis, urinary frequency, urgency and stress urinary incontinence. Estradiol hemihydrate (especially local vaginal formulations) directly acts on the urogenital mucosa to promote epithelial proliferation, increase vaginal secretions and restore mucosal elasticity, with a local therapeutic effect and minimal systemic side effects.
Improvement of neuropsychiatric symptoms: It relieves estrogen deficiency-related CNS symptoms, including insomnia, poor sleep quality, irritability, anxiety, depression, poor memory and reduced cognitive function. It also helps regulate mood and emotional stability, which is particularly important for peri-menopausal women with severe mood disorders.
Prevention of postmenopausal osteoporosis: Estrogen is a key regulator of bone metabolism—it inhibits osteoclast activity, reduces bone resorption and maintains bone mineral density (BMD). Estradiol hemihydrate is the first-line preventive agent for postmenopausal osteoporosis (especially in women within 10 years of menopause, the "critical window" for bone protection), effectively reducing the risk of osteoporotic fractures (vertebral, hip, wrist) by maintaining BMD and improving bone quality. It is also used as an auxiliary therapy for established postmenopausal osteoporosis in combination with bisphosphonates or denosumab.
China
